Estimated Annual Spending on Aducanumab in the US Medicare Program

This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

Detalles Bibliográficos
Autores principales: Mafi, John N., Leng, Mei, Arbanas, Julia Cave, Tseng, Chi-Hong, Damberg, Cheryl L., Sarkisian, Catherine, Landon, Bruce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903103/
https://www.ncbi.nlm.nih.gov/pubmed/35977233
http://dx.doi.org/10.1001/jamahealthforum.2021.4495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903103/
https://www.ncbi.nlm.nih.gov/pubmed/35977233
http://dx.doi.org/10.1001/jamahealthforum.2021.4495

Ejemplares similares